Replies to post #648 on CardioVascular BioTherapeutics (fka CVBT)

[Beachbum3232]

Don't get me wrong I'd love to see this thing take off --I've been a shareholder since 06 and like most on this board, have been on a crazy ride with this company and would love nothing more to see these products get approved and patients' lives improved.Given that many of these types of biotechs ( emerging/small/midsize) are my clients on the West Coast, I've seen 4 types of scenarios playout, 1) company licenses out technology or promising programs to large pharma 2) large pharma gives CVBT money upfront and milestone payments( or royalties) for specific achievements in a product's development including clinical trial success, FDA/European approval, launching a product successfully, and meeting predetermined sales targets or 3) small pharma gets bought by large pharma or merged with another company. 4) CVBT goes it alone which is possible but not likely in my opinion. All of which are usually positive for shareholders.